期刊文献+

原发性胆汁性肝硬化患者外周血T细胞表型及细胞因子的变化及意义 被引量:10

Significance and change of serum cytokines and T lymphocyte subsets in peripheral blood in patients with primary biliary cirrhosis
下载PDF
导出
摘要 目的观察原发性胆汁性肝硬化(PBC)患者不同时期的T淋巴细胞表型及细胞因子变化,探讨其在PBC诊治中的价值及意义。方法研究分为PBC组(32例),正常对照组(对照组,20例)。以流式细胞仪检测外周血CD4+、CD8+、CD4+/CD8+、CD4+CD25+、CD4+CD28-、CD8+CD95+T淋巴细胞;以双抗体夹心酶联免疫吸附测定(ELISA)法检测外周血细胞因子IL-2I、L-4I、L-10、TNF-α水平。结果PBC患者活动期CD4+、CD4+/CD8+、CD4+CD28-、CD8+CD95+T细胞与对照组比较明显升高(39.71±7.62)vs(27.81±3.21)(、2.31±0.23)vs(1.53±0.71)、(1.54±0.98)vs(4.15±1.89)、(9.46±4.48)vs(22.72±7.67),而CD4+CD25+与对照组比较明显降低(1.68±1.32)vs(3.99±1.21)(P<0.05)。治疗后CD4+CD25+T细胞比治疗前明显升高(P<0.05),CD4+、CD4+/CD8+的比值、CD4+CD28-和CD8+CD95+T细胞比治疗前均明显降低(P<0.05)。肝功严重损伤组外周血:CD4+CD25+T细胞明显低于肝功能轻度损伤组(1.52±0.74 vs 1.89±0.91,P<0.05),而CD4+CD28-和CD8+CD95+T细胞比例明显高于肝功能轻度损伤者(4.34±1.92 vs 2.98±1.73,23.19±7.86 vs 20.16±7.48,均P<0.05);且CD4+CD25+T细胞数量与肝功能损伤指标碱性磷酸酶(ALP)、谷丙转肽酶(GGT)呈负相关(R分别为-0.328,-0.337,均P<0.05),CD4+CD28-和CD8+CD95+T细胞数量与肝功能损伤指标ALP、GGT呈正相关(R分别为0.326,0.318,0.459,0.512,均P<0.05)。PBC活动期细胞因子IL-2、TNF-α与对照组比较明显升高(166.54±9.05)ng/L vs(25.03±4.14)ng/L(、137.13±13.49)ng/L vs(47.66±9.73)ng/L(P<0.05)。治疗后IL-10和IL-4明显升高,而IL-2和TNF-α明显降低(P<0.05)。肝功严重损伤者IL-2和TNF-α水平明显高于肝功能轻度损伤者(P<0.05);且IL-2和TNF-a水平与肝功能损伤指标ALP和GGT呈正相关(R分别为0.426、0.436、0.514、0.512,P<0.05)。结论PBC患者活动期外周血以CD4+、CD4+CD28-和CD8+CD95+T细胞升高、CD4+CD25+降低和辅助T细胞亚群1(Th1)细胞因子占优势,治疗后以CD4+CD25+升高和辅助T细胞亚群2(Th2)细胞因子占优势,提示细胞免疫和细胞因子的免疫调节在PBC发病机制中发挥重要作用。 Objective To detect serum cytokines and T lymphocyte subsets in peripheral blood in patients with primary biliary cirrhosis(PBC) and evaluate the significance for diagnosis of PBC. Methods The subjects included PBC group(32 cases) and normal control group(control group,20 cases). The number of CD4^+,CD8^+,CD4^+CD28^- ,CD4^+CD25^+and CD8^+CD95T cells were detected by flow cytometry and cytokines(IL-2, IL-4, IL-10, TNF-α) in the PBC patient serum by ELISA. Results CD4^+, CD4^+CD8^+, CD4^+CD28^- , CD8^+CD95^+T cells in PBC patients active stage were significantly higher than control group, respectively (39.71±7.62) vs (27.81± 3.21), (2.31 ± 0.23) vs (1.53±0.71),(4.15±1.89) vs (1.54±0.98), (22.72±7.67) vs (9.46±4.48). But CD4^+CD25^+decreased obviously( P 〈0.05), (1.68 ± 1.32) vs (3.99 ± 1.21) CD4^+CD25^+T cell increased obviously after therapy( P〈 0.05). CD4^+CD8^+ CD4^+ CD4^+CD28^- and CD8^+CD95^+T cell decreased obviously compared to before therapy (P 〈 0.05). The peripheral blood CD4^+CD25^+T cells in the patients with severe hepatic damnification was significantly lower compared to those of patients without severe hepatic (1.52 ±0.74 vs 1.89± 0.91, P〈0.05). The percentage of CD4^+CD28^- and CD8^+CD95^+T ceils in the patients with severe hepatic damnification was significantly higher compared to that of the patients without severe hepatic (4.34±1.92 vs 3.98±1.73,23.19±7.86 vs 21.56±7.48,all P 〈 0.05). CD4^+CD25^+T cell number of peripheral blood of PBC patients and liver functional damnification index(ALP, GGT) showed negative correlation ( r=-0. 328, -0. 337, respectively, all P〈0.05). The numbers of CD4^+CD28^-,CD8+D95^+T cell and liver functional damnification index (ALP, GGT) showed positive correlation (r = 0. 326,0. 318,0. 459,0. 512, respectively, all P 〈 0. 05). The cytokines IL-2, TNF-α were respectively in PBC active stage increased obviously compared with those of control group (25.03±4.14) ng/L vs (166.54±9.05) ng/L, (47.66± 9.73) ng/L vs (137.13 ± 13.49) ng/L( P 〈0.05). IL-10, IL-4 increased and IL-2, TNF-α decreased obviously after therapy ( P 〈0. 05). The level of IL-2 and TNF-α in the patients with severe hepatic damnification were significantly higher compared to those of the patients without severe hepatic damnification( P 〈0.05). And the level of IL-2,TNF-α and liver functional damnification index (ALP, GGT) showed positive correlation ( r = 0. 426,0. 436, 0. 514,0. 512, P 〈0.05). Conclusion The increase of CD4^+, CD4^+CD28^- and CD8^+CD95^+T cell, CD4^+CD25^+decrease and Thl cytokines are dominated in the peripheral blood of PBC patients' active stage;CD4^+CD25^+decrease and Th2 cytokines are dominated after therapy. And the cell immunity and immunity adjustment of cytokines display very important effect in PBC disease mechanism.
出处 《临床荟萃》 CAS 北大核心 2008年第7期477-481,共5页 Clinical Focus
基金 河南省教育厅自然基金项目(2007320060)
关键词 肝硬化 胆汁性 淋巴细胞亚群 细胞因子类 liver biliary, cirrhosis lymphocyte subsets cytokines
  • 相关文献

参考文献3

二级参考文献43

  • 1[1]Poupon R,Chretien Y,Poupon RE,Ballet F,Calmus Y,Darnis F.Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1:834-836
  • 2[2]Leuschner U,Fischer H,Kurtz W,Guldutuna S,Hubner K,Hellstern A,Gatzen M,Leuschner M.Ursodeoxycholic acid in primary biliary cirrhosis:results of a controlled double-blind trial.Gastroenterology 1989; 97:1268-1274
  • 3[3]Oka H,Toda G,Ikeda Y,Hashimoto N,Hasumura Y,Kamimura T,Ohta Y,Tsuji T,Hattori N,Namihisa T.A multicenter double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis.Gastroenterol Jpn 1990; 25:774-780
  • 4[4]Poupon RE,Balkau B,Eschwege E,Poupon R.A multicenter,controlled trial of ursodiol for the treatment of primary biliary cirrhosis.UDCA-PBC Study Group.N Engl J Med 1991; 324:1548-1554
  • 5[5]van de Meeberg PC,Wolfhagen FH,Van Berge-Henegouwen GP,Salemans JM,Tangerman A,van Buuren HR,van Hattum J,van Erpecum KJ.Single or multiple dose ursodeoxycholic acid for cholestatic liver disease:biliary enrichment and biochemical response.J Hepatol 1996; 25:887-894
  • 6[6]Mitchell SA,Bansi DS,Hunt N,Von Bergmann K,Fleming KA,Chapman RW.A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.Gastroenterology 2001; 121:900-907
  • 7[7]Takano S,Ito Y,Yokosuka O,Ohto M,Uchiumi K,Hirota K,Omata M.A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C.Hepatology 1994;20:558-564
  • 8[8]Lirussi F,Beccarello A,Bortolato L,Morselli-Labate AM,Crovatto M,Ceselli S,Santini G,Crepaldi G.Long-term treatment of chronic hepatitis C with ursodeoxycholic acid:influence of HCV genotypes and severity of liver disease.Liver 1999; 19:381-388
  • 9[9]Elferink RO.Cholestasis.Gut 2003; 52 Suppl 2:ii42-ii48
  • 10[10]Fabris P,Tositti G,Mazzella G,Zanetti AR,Nicolin R,Pellizzer G,Benedetti P,de Lalla F.Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis:a pilot study.Aliment Pharmacol Ther 1999; 13:1187-1193

共引文献18

同被引文献78

引证文献10

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部